cyproterone has been researched along with Meningioma* in 3 studies
3 other study(ies) available for cyproterone and Meningioma
| Article | Year |
|---|---|
First case of cyproterone acetate induced multiple meningiomas in identical female twins: A case report.
Meningiomas are the most common tumors of the central nervous system. Most meningiomas are benign and occur mainly in middle-aged women. Only a few cases of meningiomas in identical twins have been reported. Cyproterone acetate (Androcur® Bayer Healthcare SAS) (CPA) is an antiandrogenic progestin used to treat female hirsutism in some countries including France. We report a case of identical twin sisters who developed multiple, atypically located meningiomas in the setting of long-term CPA use. Eighteen-month follow-up showed spontaneous decrease of meningiomas after cessation of CPA. This case illustrates CPA's ability to induce development of atypically located meningiomas that differ even between identical twins, confirms benefit of surgical abstention, and raises questions regarding security of use of CPA. Topics: Cyproterone; Cyproterone Acetate; Female; Humans; Meningeal Neoplasms; Meningioma; Middle Aged; Progestins; Twins, Monozygotic | 2022 |
[Intra cranial meningiomas and long term use of cyproterone acetate with a conventional dose in women. A report of two cases of tumor decrease after treatment withdrawal].
The action of synthetic progestogens, prescribed at a conventional dose in women, for a meningioma, is still poorly understood, and could be related to progesterone receptors. We report two cases illustrating multiple meningiomas with stabilization or tumor reduction after withdrawal of cyproterone acetate originally prescribed for a long term period. We also review the influence of synthetic progestogens on meningiomas, particularly the impact of treatment withdrawal. Topics: Adult; Cyproterone; Cyproterone Acetate; Female; Humans; Meningeal Neoplasms; Meningioma; Treatment Outcome; Withholding Treatment | 2015 |
Abrupt regression of a meningioma after discontinuation of cyproterone treatment.
The multiplicity of meningiomas or abrupt lesion growth in patients treated with cyproterone acetate suggests that this progestative treatment may promote lesion growth. We report the rapid regression of an incidental meningioma after discontinuation of a 10-year cyproterone acetate treatment. This unique observation suggests that conservative management of meningiomas may be the best option among users of high doses of cyproterone acetate, given that spontaneous regression may occur after hormonal treatment discontinuation. Topics: Alopecia; Androgen Antagonists; Cyproterone; Female; Humans; Magnetic Resonance Imaging; Meningeal Neoplasms; Meningioma; Middle Aged; Remission Induction | 2010 |